| Product Code: ETC6181766 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Shubham Padhi | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
The Australia Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency Market focuses on the diagnosis, treatment, and management of G6PD deficiency, a genetic disorder that can cause red blood cell destruction in response to certain triggers, such as infections or specific medications. The market is primarily driven by the need for diagnostic testing, as well as medications and lifestyle management strategies to prevent hemolytic episodes. As awareness of genetic disorders increases, the demand for testing and personalized treatments for G6PD deficiency is expected to grow.
The market for treatments and diagnostics related to glucose-6-phosphate dehydrogenase (G6PD) deficiency in Australia is growing due to the rising awareness of the condition and its impact on individuals. G6PD deficiency, which can lead to hemolytic anemia, is increasingly being recognized in the context of genetic disorders. The availability of new diagnostic tools and treatments, as well as increased public health campaigns focusing on genetic testing and early diagnosis, is driving the market forward. Efforts to improve treatment options and support patients with this rare genetic disorder are central to ongoing market developments.
The Australia Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency Market faces challenges due to the limited awareness and diagnosis of the condition. G6PD deficiency is often underdiagnosed, which means there is a limited market for treatment options. Additionally, the lack of targeted therapies for G6PD deficiency, which often requires symptomatic treatment, makes it difficult to address patient needs effectively. The small patient population also limits the profitability of developing specialized drugs, and thus, the growth potential of the market is constrained.
The market for glucose 6-phosphate dehydrogenase (G6PD) deficiency treatment in Australia is gaining attention due to the increasing awareness of genetic disorders and the need for better diagnostic and therapeutic options. As G6PD deficiency affects a significant number of individuals, particularly in certain ethnic groups, investments can focus on the development of targeted therapies, gene therapies, and improved diagnostic tools. Additionally, partnerships with genetic counseling services and public health initiatives that raise awareness about this deficiency can present opportunities to grow the market for treatments and preventive measures.
The market for treatments related to glucose-6-phosphate dehydrogenase (G6PD) deficiency in Australia is driven by public health policies aimed at genetic disorders and rare diseases. The Australian governments funding for rare disease research and treatments, as well as its commitment to improving genetic screening programs, ensures that individuals with G6PD deficiency receive timely diagnosis and treatment. The TGA regulates treatments for genetic disorders to ensure their safety and efficacy. Moreover, Australia`s focus on healthcare equity and access to necessary medical treatments supports the availability of specialized therapies for G6PD deficiency.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market Overview |
3.1 Australia Country Macro Economic Indicators |
3.2 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market Revenues & Volume, 2021 & 2031F |
3.3 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market - Industry Life Cycle |
3.4 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market - Porter's Five Forces |
3.5 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market Revenues & Volume Share, By Treatment, 2021 & 2031F |
3.6 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market Revenues & Volume Share, By Symptoms, 2021 & 2031F |
3.7 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
3.8 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing awareness about genetic disorders and the importance of early detection |
4.2.2 Technological advancements in diagnostic tools and testing methods |
4.2.3 Growing research and development activities in the field of genetic disorders |
4.3 Market Restraints |
4.3.1 Limited availability of specialized healthcare professionals for accurate diagnosis and treatment |
4.3.2 High costs associated with genetic testing and treatment |
4.3.3 Lack of standardized guidelines for managing glucose 6 phosphate dehydrogenase deficiency |
5 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market Trends |
6 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market, By Types |
6.1 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market, By Treatment |
6.1.1 Overview and Analysis |
6.1.2 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market Revenues & Volume, By Treatment, 2021- 2031F |
6.1.3 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market Revenues & Volume, By Oxygen Therapy, 2021- 2031F |
6.1.4 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market Revenues & Volume, By Blood Transfusion, 2021- 2031F |
6.1.5 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market Revenues & Volume, By Genetic Counseling, 2021- 2031F |
6.1.6 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market Revenues & Volume, By Others, 2021- 2031F |
6.1.7 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market Revenues & Volume, By Diagnosis, 2021- 2031F |
6.1.8 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market Revenues & Volume, By Complete Blood Count, 2021- 2031F |
6.2 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market, By Symptoms |
6.2.1 Overview and Analysis |
6.2.2 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market Revenues & Volume, By Rapid Heart Rate, 2021- 2031F |
6.2.3 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market Revenues & Volume, By Shortness of Breath, 2021- 2031F |
6.2.4 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market Revenues & Volume, By Dark Urine, 2021- 2031F |
6.2.5 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market Revenues & Volume, By Fever, 2021- 2031F |
6.2.6 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market Revenues & Volume, By Fatigue, 2021- 2031F |
6.2.7 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market Revenues & Volume, By Dizziness, 2021- 2031F |
6.2.8 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market Revenues & Volume, By Others, 2021- 2031F |
6.2.9 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market, By End-Users |
6.3.1 Overview and Analysis |
6.3.2 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market Revenues & Volume, By Clinic, 2021- 2031F |
6.3.3 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market Revenues & Volume, By Hospital, 2021- 2031F |
6.3.4 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market, By Distribution Channel |
6.4.1 Overview and Analysis |
6.4.2 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.4.3 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.4.4 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
7 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market Import-Export Trade Statistics |
7.1 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market Export to Major Countries |
7.2 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market Imports from Major Countries |
8 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market Key Performance Indicators |
8.1 Number of genetic testing facilities offering screening for glucose 6 phosphate dehydrogenase deficiency |
8.2 Adoption rate of new diagnostic technologies in the market |
8.3 Number of clinical trials and research studies focused on glucose 6 phosphate dehydrogenase deficiency |
8.4 Percentage of healthcare providers trained in the management of genetic disorders |
9 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market - Opportunity Assessment |
9.1 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market Opportunity Assessment, By Treatment, 2021 & 2031F |
9.2 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market Opportunity Assessment, By Symptoms, 2021 & 2031F |
9.3 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market Opportunity Assessment, By End-Users, 2021 & 2031F |
9.4 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market - Competitive Landscape |
10.1 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market Revenue Share, By Companies, 2024 |
10.2 Australia Glucose 6 Phosphate Dehydrogenase Deficiency Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here